Insulin Degludec (Tresiba®, Novo Nordisk) for Diabetes
The California Technology Assessment Forum (CTAF) held a public meeting in February 2016 to discuss the comparative effectiveness and value of a drug for patients with diabetes (type 1 and type 2). The diabetes drug, insulin degludec (Tresiba®, Novo Nordisk), is a long-acting basal insulin that patients inject once per day.
Research protocol posted to Open Science Framework: https://osf.io/7awvd/
ICER’s response to public comments received on the draft report and voting questions on insulin degludec for the treatment of diabetes.